AYTU (Aytu BioPharma) Insider Ownership: 27.89 % (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AYTU Aytu BioPharma Inc AYTU
42 GF Score
Price $2.00
GF Value $0.90
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma Insider Ownership?

Aytu BioPharma AYTU 42 Insider Ownership is 27.89 % as of Sep. 15, 2026. GuruFocus rates AYTU with a GF Score™ of 42/100 and a GF Value™ of $0.90 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aytu BioPharma's insider ownership is 27.89%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aytu BioPharma's Institutional Ownership is 45.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aytu BioPharma's Float Percentage Of Total Shares Outstanding is 85.90%.

Aytu BioPharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for Aytu BioPharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma Insider Ownership Chart

Aytu BioPharma Historical Data

The historical data trend for Aytu BioPharma can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Insider Ownership 29.97 27.15 28.11 28.11 28.11 26.68 26.68 26.68 27.89 27.89
AYTU
42GF Score
Aytu BioPharma Inc AYTU
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aytu BioPharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 27.89 % mean?
Aytu BioPharma (AYTU) has a Insider Ownership of 27.89 % as of Sep. 15, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aytu BioPharma and its competitors.
Is Aytu BioPharma's Insider Ownership too high?
Aytu BioPharma's current Insider Ownership is 27.89 %. Overall, Aytu BioPharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Insider Ownership compare to BFRI and TXMD?
Aytu BioPharma's Insider Ownership of 27.89 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aytu BioPharma and its competitors. Aytu BioPharma's current Insider Ownership is 27.89 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.90, compared to a current price of $2.00 — trading 122.2% above its estimated fair value. The current Insider Ownership is 27.89 %. Aytu BioPharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Insider Ownership is 27.89 % as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (AYTU) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.00 is trading 122.2% above its estimated GF Value™ of $0.90. GuruFocus considers Aytu BioPharma to be Significantly Overvalued.

Key valuation signals for AYTU:

  • Insider Ownership: 27.89 %
  • GF Value™: $0.90 vs. price of $2.00 (122.2% above fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
42GF Score

Get the complete analysis for AYTU

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$0.90
GF Value